Scientific Programme
Bradykinin Symposium
by August 2024
Thursday, 5 September 2024
11.15-12.00
Registration and Lunch
12.00-12.15
Welcome
Markus Magerl, Berlin (Germany) | Thomas Renné, Hamburg (Germany) | Michael Bader, Berlin (Germany)
Session I: Bradykinin basics
12.15-13.00
Vascular Homeostasis over the Lifespan
Hellmut Augustin, Heidelberg (Germany)
13.00-13.30
AAE and HAE: two sides of the same coin or not?
Danny Cohn, Amsterdam (The Netherlands)
13.30-13.55
Coffee Break
13.55-14.25
Role of the kallikrein-kinin system in post-transplant focal segmental glomerulosclerosis recurrence
Joao Pesquero, Sao Paulo (Brazil)
14.25-15.05
New insights into the contact activation system
Allen Kaplan, Charleston (USA)
15.05-15.15
OP.01 | CRISPR-Based Gene Editing of KLKB1 Resulted in Long-Term Plasma Kallikrein Protein Reduction and Decreased Attack Rate in Patients With Hereditary Angioedema: Updated Results From a Phase 1 Study
Hilary Longhurst, Auckland (New Zealand)
15.15-15.25
OP.02 | Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
Jolanta Skarbaliene, Zug (Switzerland)
15.25-15.35
OP.03 | Molecular Genetics of Fletcher and Fitzgerald Traits
Anke Adenaeuer, Mainz (Germany)
15.35-15.50
Coffee Break
Session III: Kinin Receptors
15.50-16.20
Bradykinin receptors in skin
Daniela de Almeida Cabrini, Paraná (Brazil
16.20-16.50
Kinin B1 receptor in inflammatory arthritis
David A. Fox, Ann Arbor (USA)
16.50-17.00
OP.04 | Elaboration of possible targets in bradykinin-mediated endothelial barrier disruption
Raphael Möhrle, Ulm (Germany)
17.00-17.10
OP.05| B1KO mice exhibits low expression of adipogenesis markers
Gabriel de Melo Arthur, Sao Paulo (Brazil)
The E.K. Frey – E. Werle Award Ceremony
17.15-17.25
Laudation for the Gold Medal Winner Werner Müller-Esterl, Frankfurt (Germany)
17.25-17.45
Disease Patterns in the FXII & Kallikrein/Kinin System Alvin Schmaier, Cleveland OH (USA)
17.50-18:00
Awarding of the Promotion Price
18.00-22.30
Scientific Dinner
Friday, 6 September 2024
08.00-08.15
Coffee and Welcome
08.15-08.20
Summary day 1
Markus Magerl, Berlin (Germany) | Thomas Renné, Hamburg (Germany) | Michael Bader, Berlin (Germany)
Session IV: The contact system – in disease states I
08.20-08.50
An update on C1INH regulation
Steven Philip Grover, Chapel Hill (USA)
08.50-09.20
The kallikrein kinin system in bacterial infections
Sonja Oehmcke, Rostock (Germany)
09.20-09.30
OP.06 | Delayed On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported by Italian Patients
Mauro Cancian, Padova (Italy)
09.30-09.40
OP.07 | Being attack-free with garadacimab impacts quality of life in HAE
Petra Staubach, Mainz (Germany)
09.40-09.50
OP.08 | Patient-Reported Outcomes With Lanadelumab by Hereditary Angioedema Activity: EMPOWER/ENABLE Analysis
Andrea Zanichelli, Milan (Italy)
09.50-10.20
Coffee Break
Session V: Kinin activities and regulations
10.20-10.50
Polyphosphates: activators of the contact system
Reiner Mailer, Hamburg (Germany)
10.50-11.20
Molecular Dambusters: What is behind hyperpermeability in bradykinin-mediated angioedema?
Márta L Debreczeni, Budapest (Hungary)
11.20-11.30
OP.09 | Novel Rezolute Plasma Kallikrein Inhibitors Prevent Edema in Animal Models
Jeffrey Breit, Bend (USA)
11.30-11.40
OP.10 | Traffic-generated nanoparticles are strong activators of the human kallikrein/kinin system
Karin Fromell, Uppsala (Sweden)
11.40-11.50
OP.11 | Heme binds to and activates factor XII leading to bradykinin release during hemolysis
Alexandra Gerogianni, Lund (Sweden)
11.50-12.00
OP.12 | A specific, sensitivity assay measuring patient sample plasma kallikrein activity
Daniel Lee, Cambridge (USA)
12.00-12.20
Coffee Break
Session VI: The contact system – in disease states II
12.20-12.50
Current status – modern new therapies
Timothy Craig, Hershey, PA (USA)
12.50-13.00
OP.13 | The Kallikrein-kinin system is an early biomarker of SARS-CoV-2 infection
Barbro Persson, Uppsala (Sweden)
13.00-13.10
OP.14 | KONFIDENT-S Interim Analysis: Sebetralstat for Hereditary Angioedema Attacks Including Laryngeal
Henriette Farkas, Budapest (Hungary)
13.10-13.20
OP.15 | Impact of Factor XII, Prekallikrein and C1-Inhibitor in Renal Fibrosis
Rodrigo Silva-Aguiar, Cleveland (USA)
13.20-13.30
OP.16 | Pooled Sebetralstat Placebo-controlled Safety for On-demand Treatment of Hereditary Angioedema
Emel Aygören-Pürsün, Frankfurt (Germany)
13.30-13.40
OP.17 | Lanadelumab Effectiveness and Safety by Disease Activity: EMPOWER/ENABLE Pooled Analysis
Andrea Zanichelli, Milan (Italy)
13.40-14.30
Lunch
Session VII: Hereditary angioedema
14.30-14.55
Current and prospective targets of pharmacologic therapies
Lauré M Fijen, Amsterdam (The Netherlands)
14.55-15.05
OP.18 | Reduction in Plasma Kallikrein by CRISPR-Based Gene Editing of KLKB1 Did Not Alter Coagulation in the Phase 1 Study of Patients With Hereditary Angioedema
Remy S Petersen, Amsterdam (The Netherlands)
15.05-15.15
OP.19 | Prophylactic Treatment With Deucrictibant Improves HAE Disease Control and HRQoL
Markus Magerl, Berlin (Germany)
15.15-15.25
OP.20 | Rare and complexes connective tissue diseases in patients with C1-inhibitor deficiency Hereditary Angioedema: first evidence on prevalence and distribution from a large Italian cohort study
Riccardo Senter, Padova (Italy)
15.25-15.35
OP.21 | Angioedema due to familial acquired C1-inhibitor deficiency
Ramon Lleonart Bellfill, Barcelona (Spain)
15.35-16.15
Poster Session
Session VIII: HAE Worldwide
16.15-16.40
News from the world of angioedema
Anete S. Grumach, Santo André (Brazil)
16.40-16.50
OP.22 | Screening Programme Outreach for Testing Hereditary Angioedema (SPOT-HAE): Validation and Utilizing Dried Blood Spot for Family Screening
Jane C Y Wong, Hong Kong (China)
16.50-17.00
OP.23 | A physician-based Brazilian Registry for Hereditary Angioedema: first 704 patients
José Eduardo Seneda Lemos, Sao Paulo (Brazil)
17.00-17.10
OP.24 | Psychometric analysis of AE-QoL from HAE subsamples in observational studies
Thomas Buttgereit, Berlin (Germany)
17.10-17.25
Conclusion: What did we hear? What take we home?
Markus Magerl, Berlin (Germany)
17.25-17.40
Closing remarks
Markus Magerl, Berlin (Germany) | Thomas Renné, Hamburg (Germany) | Michael Bader, Berlin (Germany)
If you need child care, please contact our professional congress organiser via bradykinin@remember-management.de.
